Premium
Use of neurotransmitter regulators in functional gastrointestinal disorders based on symptom analysis
Author(s) -
Luo Qing Qing,
Chen Sheng Liang
Publication year - 2017
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12472
Subject(s) - medicine , neurotransmitter , tricyclic , anxiety , serotonin , reuptake inhibitor , neurotransmitter systems , neurotransmitter agents , antidepressant , pharmacology , intensive care medicine , psychiatry , dopamine , receptor
It has been a great challenge for gastroenterologists to cope with functional gastrointestinal disorders ( FGIDs ) in clinical practice due to the contemporary increase in stressful events. A growing body of evidence has shown that neuroregulators such as anti‐anxiety agents and antidepressants function well on FGIDs , particularly in cases that are refractory to classical gastrointestinal ( GI ) medications. Among these central‐acting agents, small individualized doses of tricyclic antidepressants and selective serotonin reuptake inhibitors are usually recommended as a complement to routine GI management. When these drugs are chosen to treat FGIDs , both their central effects and the modulation of peripheral neurotransmitters should be taken into consideration. In this article we recommend strategies for choosing drugs based on an analysis of psychosomatic GI symptoms. The variety and dosage of the neurotransmitter regulators are also discussed.